Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
about
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerGood clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptorHigh-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer PatientsProtein-structure-guided discovery of functional mutations across 19 cancer typesIs There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsClinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceEffectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.Differential sensitivity of ERBB2 kinase domain mutations towards lapatinibOncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancerRapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugsLung cancer mutations and use of targeted agents in HispanicsNext-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytologyEpidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceComparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancerBuilding a personalized medicine infrastructure at a major cancer center.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications.Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.BIBW 2992 in non-small cell lung cancer.Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance.Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.[Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report].EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapyIsolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells.Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation.Understanding and targeting resistance mechanisms in NSCLC.Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
P2860
Q26852215-DA57121B-274C-4A16-A0BD-BFD15D177015Q27851566-9E1AADF5-16F7-489A-872B-D416D3B95568Q27853109-D549BD29-963C-46E4-A5CE-439E10F83765Q28382921-8D4B1B14-D111-464F-8FE8-DB5674D3766DQ28551235-822C77E7-C0EA-478F-88DA-CC8AAC4A1659Q30389229-72A8486D-FBFF-4304-B59E-B9D2D13BD1E6Q33423782-71737E4C-BBEC-4AE3-A059-FADB27539D38Q33769838-9B08F9BF-8DA2-46A4-A876-A59CADDC17E8Q34011705-BF144E74-4CCE-4827-9672-39F7F504B566Q34041701-9BC540BA-E0FC-4822-942F-1F376416B048Q34064653-A5969F80-85E9-4A66-93B2-2512806FA920Q35007438-55EE1442-FEEC-446C-B764-9C1AC0E83C66Q35059352-26128903-A157-47AE-B66F-88EF5C355266Q35636924-2244C8D4-08B8-488E-B35E-2AF64E15218CQ35726787-77B79B6F-5CD3-48A3-AD45-703EB03AA869Q36503084-FA744E68-DBDD-49AE-8F36-C1C966A06290Q36786024-15B78C0F-6EA6-49D7-9EC3-75F28FFECC6DQ36929987-E479A693-D0DF-4520-9EE9-9446ED53AE23Q37060709-44D5DA99-BCE8-4739-B2C1-B496A9D9D034Q37334996-0884D962-6076-4752-9F2C-48CFCFE3AAC0Q37432540-C407BC83-DD4A-46AF-BB4F-90DC60F98C48Q37641681-35E7FEAF-C48A-4522-BE63-9FB65360E177Q37643945-C5CE116B-70DD-4D03-8EB2-0D9D0B8BE438Q37697306-78B6A43E-D08D-4D9A-B596-15597E4C1013Q37841599-BCCD7E72-870F-4CD3-B6CE-FA1639AFAA09Q38767492-BFCFFB16-661D-4583-8003-F22A034C0AD8Q38927992-B5DAF3E3-1A31-4579-929D-E2464B1DB203Q39129178-961797D2-B507-4648-81A3-F65CBEB52929Q39198672-126FD63B-22F9-4DD7-9CA5-25CE50A0E982Q39467165-8D5440DB-27F5-4174-B530-85C032BC3BDEQ39716869-0D22A9B0-CAE7-4F96-A211-44ED8EBE3FC9Q40048246-2641E5C4-D0A7-4F46-BDE7-AB26EB5CE687Q41348195-B5673DDA-3DD0-4C86-9099-1A2D8BE23C65Q42101274-362466BB-0A44-44CB-9D10-6AC90B237122Q42146311-D4B2DAE0-8197-4A7A-8948-403FEC837351Q42186051-07D2FD06-87F1-42AF-B76A-BC3BEE7EA74EQ46915997-6EE03DE1-0D2F-4143-A060-26ECAA87E5C6Q47261717-AF76EAD9-1F85-444C-AB12-248D065F75F1Q47590798-9F9AE89F-8FF8-4B3D-88DA-2706C29CAAD9Q47611571-12854B36-FC12-460D-AFE2-13A3A1A2C770
P2860
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Functional analysis of epiderm ...... ons for EGFR targeted therapy.
@en
Functional analysis of epidermal growth factor receptor
@nl
type
label
Functional analysis of epiderm ...... ons for EGFR targeted therapy.
@en
Functional analysis of epidermal growth factor receptor
@nl
prefLabel
Functional analysis of epiderm ...... ons for EGFR targeted therapy.
@en
Functional analysis of epidermal growth factor receptor
@nl
P2093
P1476
Functional analysis of epiderm ...... ons for EGFR targeted therapy.
@en
P2093
Christian Peschel
Justus Duyster
Nikolas von Bubnoff
Rama Krishna Kancha
P304
P356
10.1158/1078-0432.CCR-08-1757
P407
P577
2009-01-01T00:00:00Z